Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study

Ali Ahmed1, Michael W Rich, Paul W Sanders

  • 1University of Alabama at Birmingham, Birmingham, Alabama, USA. aahmed@uab.edu

Insights

Chronic kidney disease (CKD) increases mortality risk in heart failure (HF) patients. This risk is significantly higher in diastolic heart failure than systolic heart failure, regardless of left ventricular ejection fraction (LVEF).

Area of Science:

  • Cardiology
  • Nephrology
  • Clinical Research

Background:

  • Chronic kidney disease (CKD) is a prevalent condition associated with increased mortality in patients with heart failure (HF).
  • The impact of CKD on mortality within different HF classifications, specifically systolic HF (reduced left ventricular ejection fraction, LVEF) versus diastolic HF (preserved LVEF), remains unclear.

Purpose of the Study:

  • To investigate whether the association between CKD and mortality differs between patients with systolic HF and diastolic HF.
  • To analyze the relationship between CKD, LVEF, and mortality risk across various LVEF subgroups.

Main Methods:

  • Utilized data from 7,788 patients in the Digitalis Investigation Group trial, identifying 3,527 (45%) with CKD (eGFR <60 ml/min/1.73 m2).
  • Employed propensity score matching to create comparable groups of patients with and without CKD.
  • Calculated hazard ratios (HR) and confidence intervals (CI) to assess mortality risk associated with CKD in different HF types and LVEF categories.

Main Results:

  • Overall, CKD was associated with a 22% increased mortality risk (HR 1.22, 95% CI 1.09-1.36).
  • CKD-associated mortality was significantly higher in diastolic HF (HR 1.71, 95% CI 1.21-2.41) compared to systolic HF (HR 1.19, 95% CI 1.07-1.32), with a significant interaction (p=0.034).
  • A graded association between CKD and mortality was observed across LVEF subgroups, with the highest risk in LVEF >55% (HR 2.33, 95% CI 1.34-4.06).

Conclusions:

  • CKD confers a higher mortality risk in patients with diastolic HF compared to those with systolic HF.
  • Patients with diastolic HF should be screened for CKD.
  • Further investigation into the role of renin-angiotensin system inhibitors in patients with diastolic HF and CKD is warranted.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...